Fred M. Schwarzer
Net Worth
Last updated:
What is Fred M. Schwarzer net worth?
The estimated net worth of Mr. Fred M. Schwarzer is at least $3,247,296 as of 13 Sep 2024. He owns shares worth $320,159 as insider, has earned $384,577 from insider trading and has received compensation worth at least $2,542,560 in IGM Biosciences, Inc..
What is the salary of Fred M. Schwarzer?
Mr. Fred M. Schwarzer salary is $847,520 per year as Chief Executive Officer, Pres & Director in IGM Biosciences, Inc..
How old is Fred M. Schwarzer?
Mr. Fred M. Schwarzer is 72 years old, born in 1953.
What stocks does Fred M. Schwarzer currently own?
As insider, Mr. Fred M. Schwarzer owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| IGM Biosciences, Inc. (IGMS) | Chief Executive Officer, Pres & Director | 250,124 | $1.28 | $320,159 |
What does IGM Biosciences, Inc. do?
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Fred M. Schwarzer insider trading
IGM Biosciences, Inc.
Mr. Fred M. Schwarzer has made 10 insider trades between 2022-2024, according to the Form 4 filled with the SEC. Most recently he sold 3,946 units of IGMS stock worth $45,533 on 13 Sep 2024.
The largest trade he's ever made was exercising 7,955 units of IGMS stock on 16 Dec 2022. As of 13 Sep 2024 he still owns at least 250,124 units of IGMS stock.
IGM Biosciences key executives
IGM Biosciences, Inc. executives and other stock owners filed with the SEC:
- Dr. Bruce A. Keyt (72) Chief Scientific Officer
- Dr. Shinyu Chen M.D., Ph.D. (56) Consultant
- Mr. Fred M. Schwarzer (72) Chief Executive Officer, Pres & Director